Sponsor

Affiris AG

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Affiris AG appears in 17 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials17
Recruiting shown0
Roles1
SourceClinicalTrials.gov
Advertisement

Clinical trials

17 shown
Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)NCT02618941 · lead sponsor · 2016-02-02
COMPLETED
Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's DiseaseNCT02267434 · lead sponsor · 2014-12-01
COMPLETED
Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical ActivityNCT02216188 · lead sponsor · 2014-08-01
COMPLETED
Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006NCT02008513 · lead sponsor · 2013-06-01
TERMINATED
AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01ANCT01885494 · lead sponsor · 2013-06-01
COMPLETED
Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's DiseaseNCT01568099 · lead sponsor · 2012-02-01
COMPLETED
Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AD03 Applied During AFF005ANCT01568086 · lead sponsor · 2011-12-01
TERMINATED
Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's DiseaseNCT01357629 · lead sponsor · 2011-07-01
TERMINATED
Safety and Tolerability of AFFITOPE AD03NCT01309763 · lead sponsor · 2010-10-01
COMPLETED
Clinical- and Immunological Activity, Safety and Tolerability of Different Doses / Formulations of AFFITOPE AD02 in Early Alzheimer's DiseaseNCT01117818 · lead sponsor · 2010-09-01
COMPLETED
AD01 Follow up Extension VisitNCT01225809 · lead sponsor · 2010-09-01
COMPLETED
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02NCT01093664 · lead sponsor · 2009-10-01
COMPLETED
Long-term Safety and Tolerability of AFFITOPE AD02NCT00711321 · lead sponsor · 2008-11-01
COMPLETED
Long-term Safety and Tolerability of AFFITOPE AD01NCT00711139 · lead sponsor · 2008-06-01
COMPLETED
Tolerability and Safety of Subcutaneous Administration of AFFITOPE AD02 in Mild to Moderate Alzheimer's DiseaseNCT00633841 · lead sponsor · 2008-02-01
COMPLETED
Tolerability and Safety of Subcutaneous Administration of Affitope AD01 in Mild to Moderate Alzheimer's DiseaseNCT00495417 · lead sponsor · 2007-07-01
COMPLETED
Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA PatientsNCT02758730 · lead sponsor
WITHDRAWN

Sponsor roles

lead sponsor17
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.